According to the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) Obesity Clinical Practice Guidelines, obese patients receiving incretin-based therapies for weight loss should be monitored for the development of pancreatitis
While GLP-1 medications are effective for many people, they are not suitable for everyone
PlexusDx maps 14 peptide-related pathways and 150+ genetic insights, giving you and your provider a precision-based roadmap for your restart protocol
At Skin House, our physician-supervised weight loss programs use GLP-1 receptor agonist medications tailored to your body, your health, and your goals
They are glucagon-like peptide-1 (GLP-1) receptor agonists that reduce blood sugar and help with weight loss by mimicking the bodys endogenous GLP-1 hormone
Anthem is one of these licensees, operating BCBS plans in states including California, New York, Georgia, Virginia, and several others